• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Professional Introduction to Compound with CAS No. 1421604-44-5 and Product Name: Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate

The compound with the CAS number 1421604-44-5 and the product name Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique structural features, has garnered attention for its potential applications in medicinal chemistry and drug development. The presence of a tert-butyl group and a difluoromethyl-substituted cyclopentyl moiety in its molecular framework contributes to its distinct chemical properties, making it a subject of interest for researchers exploring novel therapeutic agents.

Recent studies have highlighted the importance of fluorinated compounds in the design of bioactive molecules. The difluoromethyl group in the structure of Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate is particularly noteworthy, as it has been shown to enhance metabolic stability and binding affinity in various drug candidates. This feature is especially relevant in the context of developing small-molecule inhibitors targeting enzymes involved in critical biological pathways. The tert-butyl carbamate moiety further contributes to the compound's solubility and bioavailability, making it a promising candidate for further investigation.

In the realm of medicinal chemistry, the synthesis and characterization of this compound have opened new avenues for research. The structural motif of Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate has been explored in the context of modulating enzyme activity, particularly in kinases and proteases that play pivotal roles in diseases such as cancer and inflammatory disorders. Preliminary computational studies suggest that this compound exhibits favorable interactions with its intended biological targets, which could lead to the development of novel therapeutic strategies.

The synthesis of Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate involves multi-step organic transformations, showcasing the expertise required in modern pharmaceutical synthesis. The introduction of the difluoromethyl group into the cyclopentyl ring is a challenging yet rewarding aspect of its preparation. Advanced synthetic methodologies, including transition-metal-catalyzed reactions and cross-coupling techniques, have been employed to achieve high yields and purity. These synthetic approaches not only highlight the ingenuity of organic chemists but also underscore the importance of innovative strategies in drug discovery.

From a pharmacological perspective, Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate has been investigated for its potential as an antineoplastic agent. Preclinical studies have demonstrated that compounds with similar structural features exhibit inhibitory effects on tumor growth by interfering with key signaling pathways. The combination of the tert-butyl group, which enhances lipophilicity, and the difluoromethyl group, which improves metabolic stability, makes this compound an attractive candidate for further development. Additionally, its cyclopentyl backbone provides a rigid scaffold that can be optimized for better binding affinity.

The role of computational chemistry in understanding the behavior of this compound cannot be overstated. Molecular modeling techniques have been instrumental in predicting how Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate interacts with biological targets at the atomic level. These simulations have provided valuable insights into optimizing its structure for enhanced efficacy and reduced side effects. By leveraging computational tools, researchers can accelerate the drug discovery process, reducing both time and cost associated with traditional experimental methods.

In conclusion, Tert-butyl N-2-(difluoromethyl)cyclopentylcarbamate (CAS No. 1421604-44-5) represents a compelling example of how structural innovation can lead to novel therapeutic agents. Its unique combination of functional groups and its promising preclinical results make it a valuable asset in ongoing research efforts. As our understanding of disease mechanisms continues to evolve, compounds like this one will play an increasingly important role in developing targeted therapies that address unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)